Expression and immunogenicity evaluation of a novel Lentiviral multi- epitope vaccine against Leishmania major in BALB/c mice.

ABSTRACT:

Background

Nowadays, the prevention of parasitic diseases including leishmaniasis, particularly cutaneous leishmaniasis as the smost common type of the disease, has increased health concerns around the world. Although some drugs such as Glucantim and Amphotericin B are approved, they have side effects. Therefore, treatment without side effects is a priority.

Methodology

In this study, the recombinant lentiviral vaccine containing a novel multi-epitope of KMP11 and HASPB of Leishmania major (L. major) was synthesized. The multi-epitope construct was previously designed in silico, subcloned into the pCDH513 lentiviral vector, and the recombinant lentiviral multi-epitope vaccine (rLV-multi-epitope) was synthesized in HEK293T cells using the packaging vectors. The Western Blotti

SUBMITTER: Rabienia M 

PROVIDER: S-EPMC12211387 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature